Nuclear Medicine/ Radiopharmaceuticals Market 2020 | Industry Trends, Growth Drivers, Competitive Landscape, Regional Analysis 2026

The MarketWatch News Department was not involved in the creation of this content.

Dec 04, 2020 (The Expresswire) —
The global “Nuclear Medicine/Radiopharmaceuticals Market” size is projected to reach USD 9.67 billion by 2026. According to a report published by Fortune Business Insights, titled “Nuclear Medicine/Radiopharmaceuticals Market Size, Share and Industry Analysis, By Type (Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals), By Application (Neurology, Cardiology, Oncology, and Others), By End User (Hospitals and Clinics, Diagnostic Centres, and Others) and Regional Forecast, 2019-2026,” the market was valued at USD 4.86 billion in 2018. Driven by increasing number of successful clinical trials, the market will exhibit a CAGR of 9.2% from 2019-2026.

Leading Players operating in the Nuclear Medicine/ Radiopharmaceuticals Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

  • Lantheus Medical Imaging, Inc.
  • Cardinal Health
  • Norgine B.V.
  • Curium
  • Advanced Accelerator Applications (Novartis AG)
  • Bracco Diagnostic Inc.
  • Jubilant Life Sciences Limited
  • Bayer AG
  • Eli Lilly and Company
  • GE Healthcare (General Electric Company)

Request a Sample Copy of the Research Report:https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/nuclear-medicine-radiopharmaceuticals-market-101812

Radiopharmaceuticals are substances that are used to diagnose specific medical problems or diseases. Increasing imaging capabilities and efficiencies have led to a wide product adoption across the world. Increasing number of successful clinical trials associated with radiopharmaceuticals will fuel the demand for the product. Recent drug application area discoveries have showcased promise for the companies operating in the market. Technological advancements in nuclear imaging and their applications in diagnosis of cancer and other serious diseases have opened up a huge potential for growth. Growing awareness regarding the adverse effects of chronic diseases, and the need for early diagnosis will aid market growth.

The advancements in imaging systems have played a major role in the growth of the market. Companies are putting in increased efforts towards the manufacturing of diagnostic radiopharmaceuticals. Increasing investments in the research and development (RandD) will create several growth opportunities for market growth. At the same instance, therapeutic radiopharmaceuticals can be used for the treatment of critical illnesses such as cancers.

Have Any Query? Ask Our Experts:https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/nuclear-medicine-radiopharmaceuticals-market-101812

Detailed Table of Content:

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Key Insights
    • Installed Base of PET/PET-CT Scanners For Key Countries, 2015 and 2018
    • Installed Base of Gamma Cameras for Key Countries, 2018
    • PET/PET-CT Procedure Volume for Key Countries, 2018
    • Reimbursement Scenario in Key Countries
    • New Product Launches
    • Key Industry Developments
    • Pipeline Analysis
  • Global Nuclear Medicine/ Radiopharmaceuticals Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast By Type
      • Diagnostic Radiopharmaceuticals
        • PET Radiopharmaceuticals
          • FDG-PET/18F
          • 68Ga
          • 68Cu
          • 11C
          • Others
        • SPECT Radiopharmaceuticals
          • Technetium-99m
          • Iodine-123
          • Xenon-133
          • Thallium-201
          • Others
        • Therapeutic Radiopharmaceuticals
      • Market Analysis, Insights and Forecast By Application
        • Neurology
        • Cardiology
        • Oncology
        • Others
      • Market Analysis, Insights and Forecast By End User
        • Hospitals and Clinics
        • Diagnostic Centers
        • Others
      • Market Analysis, Insights and Forecast By Region
        • North
Read more

Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2030 – Focus on the Supply Chain Model of Medical Isotope Mo-99 (Tc-99m)

DUBLIN, Oct. 21, 2020 /PRNewswire/ — The “Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030” report has been added to ResearchAndMarkets.com’s offering.

The ‘Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030’ report provides a detailed study on the current market landscape and future potential of the companies having the capabilities to manufacture radiopharmaceuticals. In addition, the study features an in-depth analysis, highlighting the capabilities of a diverse set of industry stakeholders.

Over the years, medical research teams across the world have gradually tapped into the vast potential of radiopharmaceuticals and nuclear medicines. In fact, the technology that is now used in this field is reported to have witnessed significant evolution, in terms of technological sophistication. As a result, the demand for such specialized chemicals has grown at an exponential rate.

However, the development and production of radiopharmaceuticals is inherently complex, and requires specialized facilities and operational expertise. Therefore, acquiring the necessary technical acumen and infrastructure to support such operations is not a feasible option for pharmaceutical companies, owing to a number of associated clauses and concerns (such as need for high capital investments, unique operating licenses and compliance to special regulatory requirements).

Scope Of the Report

  • A detailed assessment of the current market landscape with respect to the players (industry and non-industry) involved in manufacturing radiopharmaceuticals. It features information on the year of establishment, company size, purpose of production (fulfilling in-house requirements / for contract services), location of headquarters, location of manufacturing facilities, scale of production, applications of radiopharmaceuticals (in diagnosis, therapeutics and theranostics), type of diagnostic radiopharmaceuticals (PET and SPECT), type of therapeutic radiopharmaceuticals (alpha emitters, beta emitters and others), target therapeutic area (cardiology, oncology, neurology, thyroid and others) and services offered.
  • An insightful four-dimensional comparison of the radiopharmaceutical manufacturers, based on supplier power (year of establishment), product portfolio (number of isotopes being manufactured for various applications targeting different therapeutic areas) of the manufacturer, scale at which they manufacture their respective products and company size.
  • Tabulated profiles of key industry players based in North America, Europe and Asia-Pacific (shortlisted based on the company size of the players), featuring a brief overview of the company, a list of products and manufacturing facilities, recent developments and an informed future outlook.
  • An analysis of recent partnerships and collaborations inked in this domain since 2017, based on several parameters, such as the type of partnership, year of partnership, type of radioisotope involved, therapeutic area mentioned in the agreement, application of the radioisotope mentioned in the agreement, and a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.
  • A detailed discussion on the supply chain model of medical isotope Mo-99 (Tc-99m), highlighting the main steps of the supply chain, from irradiation of uranium targets in nuclear research reactors to the administration of Tc-99m to patients. Along with this, it describes the structure of the
Read more